{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:02:08Z","timestamp":1789009328459,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12072-021-10295-3","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T22:02:49Z","timestamp":1643061769000},"page":"282-293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5082-3967","authenticated-orcid":false,"given":"Eiichi","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Koyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aritsune","family":"Ooho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Dohmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeaki","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Amagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kuniyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ichiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Kyushu University Liver Disease Study (KULDS) Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"10295_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095\u20132128","journal-title":"Lancet"},{"key":"10295_CR2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546\u20131555","journal-title":"Lancet"},{"key":"10295_CR3","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u20131599","journal-title":"Hepatology"},{"key":"10295_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u2013398","journal-title":"J Hepatol"},{"key":"10295_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398","journal-title":"Hepatol Int"},{"key":"10295_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","volume":"67","author":"AS Lok","year":"2017","unstructured":"Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. J Hepatol. 2017;67:847\u2013861","journal-title":"J Hepatol"},{"issue":"72","key":"10295_CR7","first-page":"539","volume":"2020","author":"M Cornberg","year":"2019","unstructured":"Cornberg M, Lok AS, Terrault NA, Zoulim F. EASL-AASLD HBV treatment endpoints conference faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014report from the 2019 EASL-AASLD HBV treatment endpoints conference\u2021. J Hepatol. 2019;2020(72):539\u2013557","journal-title":"J Hepatol"},{"key":"10295_CR8","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.2147\/DDDT.S126742","volume":"11","author":"E Ogawa","year":"2017","unstructured":"Ogawa E, Furusyo N, Nguyen MH. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:3197\u20133204","journal-title":"Drug Des Devel Ther"},{"key":"10295_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","volume":"63","author":"AS Lok","year":"2016","unstructured":"Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63:284\u2013306","journal-title":"Hepatology"},{"key":"10295_CR10","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","volume":"139","author":"G Woo","year":"2010","unstructured":"Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139:1218\u20131229","journal-title":"Gastroenterology"},{"key":"10295_CR11","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"319","author":"LSY Tang","year":"2018","unstructured":"Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319:1802\u20131813","journal-title":"JAMA"},{"key":"10295_CR12","first-page":"59","volume":"18","author":"JL Casado","year":"2016","unstructured":"Casado JL. Renal and bone toxicity with the use of tenofovir: understanding at the end. AIDS Rev. 2016;18:59\u201368","journal-title":"AIDS Rev"},{"key":"10295_CR13","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","volume":"60","author":"M Buti","year":"2015","unstructured":"Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457\u20131464","journal-title":"Dig Dis Sci"},{"key":"10295_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185\u2013195","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10295_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196\u2013206","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10295_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672\u2013681","journal-title":"J Hepatol"},{"key":"10295_CR17","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/liv.14482","volume":"40","author":"E Ogawa","year":"2020","unstructured":"Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578\u20131589","journal-title":"Liver Int"},{"key":"10295_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u2013992","journal-title":"Am J Kidney Dis"},{"key":"10295_CR19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/j.1872-034X.2011.00869.x","volume":"41","author":"E Ogawa","year":"2011","unstructured":"Ogawa E, Furusyo N, Murata M, Ohnishi H, Toyoda K, Taniai H, et al. Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. Hepatol Res. 2011;41:1178\u20131188","journal-title":"Hepatol Res"},{"key":"10295_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/jmv.25644","volume":"92","author":"Y Uchida","year":"2020","unstructured":"Uchida Y, Nakao M, Tsuji S, Uemura H, Kouyama JI, Naiki K, et al. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate. J Med Virol. 2020;92:329\u2013338","journal-title":"J Med Virol"},{"key":"10295_CR21","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14786","volume":"41","author":"ZB Li","year":"2021","unstructured":"Li ZB, Li L, Niu XX, Chen SH, Fu YM, Wang CY, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int. 2021;41:1254\u20131264","journal-title":"Liver Int"},{"key":"10295_CR22","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.14309\/ajg.0000000000001157","volume":"116","author":"MH Nguyen","year":"2021","unstructured":"Nguyen MH, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh HN, et al. Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir. Am J Gastroenterol. 2021;116:1264\u20131273","journal-title":"Am J Gastroenterol"},{"key":"10295_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/jvh.13053","volume":"26","author":"TL Fong","year":"2019","unstructured":"Fong TL, Lee BT, Tien A, Chang M, Lim C, Ahn A, et al. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. J Viral Hepat. 2019;26:561\u2013567","journal-title":"J Viral Hepat"},{"key":"10295_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","volume":"5","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5:441\u2013453","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10295_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31793","author":"H Toyoda","year":"2021","unstructured":"Toyoda H, Leong J, Landis C, Atsukawa M, Watanabe T, Huang DQ, et al. Treatment and renal outcomes up to 96 weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice. Hepatology. 2021. https:\/\/doi.org\/10.1002\/hep.31793","journal-title":"Hepatology."},{"key":"10295_CR26","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.26301","volume":"58","author":"GL Wong","year":"2013","unstructured":"Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537\u20131547","journal-title":"Hepatology"},{"key":"10295_CR27","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","volume":"142","author":"TC Tseng","year":"2012","unstructured":"Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140\u20131149","journal-title":"Gastroenterology"},{"key":"10295_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","volume":"70","author":"TC Yip","year":"2019","unstructured":"Yip TC, Wong GL, Chan HL, Tse YK, Lam KL, Lui GC, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70:361\u2013370","journal-title":"J Hepatol"},{"key":"10295_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhep.2008.10.014","volume":"50","author":"P Bedossa","year":"2009","unstructured":"Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50:1\u20133","journal-title":"J Hepatol"},{"key":"10295_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ejrad.2009.10.012","volume":"78","author":"AA Razek","year":"2011","unstructured":"Razek AA, Abdalla A, Omran E, Fathy A, Zalata K. Diagnosis and quantification of hepatic fibrosis in children with diffusion weighted MR imaging. Eur J Radiol. 2011;78:129\u2013134","journal-title":"Eur J Radiol"},{"key":"10295_CR31","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s11547-014-0408-x","volume":"119","author":"AAKA Razek","year":"2014","unstructured":"Razek AAKA, Khashaba M, Abdalla A, Bayomy M, Barakat T. Apparent diffusion coefficient value of hepatic fibrosis and inflammation in children with chronic hepatitis. Radiol Med. 2014;119:903\u2013909","journal-title":"Radiol Med"},{"key":"10295_CR32","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00261-015-0391-2","volume":"40","author":"AA Razek","year":"2015","unstructured":"Razek AA, Massoud SM, Azziz MR, El-Bendary MM, Zalata K, Motawea EM. Prediction of esophageal varices in cirrhotic patients with apparent diffusion coefficient of the spleen. Abdom Imaging. 2015;40:1465\u20131469","journal-title":"Abdom Imaging"},{"key":"10295_CR33","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3748\/wjg.v25.i11.1366","volume":"25","author":"T Besheer","year":"2019","unstructured":"Besheer T, Elalfy H, Abd El-Maksoud M, Abd El-Razek A, Taman S, Zalata K, et al. Diffusion-weighted magnetic resonance imaging and micro-RNA in the diagnosis of hepatic fibrosis in chronic hepatitis C virus. World J Gastroenterol. 2019;25:1366\u20131377","journal-title":"World J Gastroenterol"},{"key":"10295_CR34","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4853","author":"B Surial","year":"2021","unstructured":"Surial B, Mugglin C, Calmy A, Cavassini M, G\u00fcnthard HF, St\u00f6ckle M, et al. Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study. Ann Intern Med. 2021. https:\/\/doi.org\/10.7326\/M20-4853","journal-title":"Ann Intern Med."},{"key":"10295_CR35","first-page":"490A","volume":"72","author":"HLY Chan","year":"2020","unstructured":"Chan HLY, Buti M, Agarwal K, et al. Maintenance of high levels of viral suppression and improved safety profile of tenofovir alafenamide relative to tenofovir disoproxil fumarate in chronic hepatitis B patients treated for 5 years in 2 ongoing phase 3 studies. Hepatology. 2020;72:490A","journal-title":"Hepatology"},{"key":"10295_CR36","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1002\/hep.22885","volume":"49","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49:S185\u2013S195","journal-title":"Hepatology"},{"key":"10295_CR37","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cgh.2012.04.008","volume":"10","author":"RG Gish","year":"2012","unstructured":"Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:941\u2013946","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10295_CR38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","volume":"33","author":"RD Lindeman","year":"1985","unstructured":"Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278\u2013285","journal-title":"J Am Geriatr Soc"},{"key":"10295_CR39","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jmv.25692","volume":"92","author":"N Tamaki","year":"2020","unstructured":"Tamaki N, Kurosaki M, Nakanishi H, Itakura J, Inada K, Kirino S, et al. Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B. J Med Virol. 2020;92:1355\u20131358","journal-title":"J Med Virol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10295-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10295-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10295-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T06:37:28Z","timestamp":1650177448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10295-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10295"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10295-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-268836\/v1","asserted-by":"object"}]},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eiichi Ogawa has received speaker fees from Gilead Sciences and AbbVie. Makoto Nakamuta, Toshimasa Koyanagi, Aritsune Ooho, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Takeaki Satoh, Kazuhiro Takahashi, Koichi Azuma, Nobuyuki Yamashita, Naoki Yamashita, Rie Sugimoto, Hiromasa Amagase, Masami Kuniyoshi, Yasunori Ichiki, Chie Morita, Masaki Kato, Shinji Shimoda, Hideyuki Nomura, and Jun Hayashi declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the STROBE statement. It was approved by the Ethics Committees of Kyushu University Hospital and each study site and is registered as a clinical study on the University Hospital Medical Information Network (ID 000034696).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}